Oral Small-Molecule Kinase Inhibitor

Mechanism

Related News

Pfizer's Braftovi Combo Shows Improved Survival in Metastatic Colorectal Cancer Trial

Feb 17, 2026

Pfizer announced positive progression-free survival results from the BREAKWATER trial evaluating Braftovi in combination with cetuximab and Folfiri in previously untreated metastatic colorectal cancer patients with BRAF V600E mutation.

Pfizer's BRAFTOVI Regimen Shows Significant PFS Improvement in Colorectal Cancer Trial

Feb 17, 2026

Pfizer announced positive results from Cohort 3 of the Phase 3 BREAKWATER trial, showing BRAFTOVI combined with cetuximab and FOLFIRI significantly improved progression-free survival in previously untreated BRAF V600E-mutant metastatic colorectal cancer patients.